{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:25:36Z","timestamp":1789457136259,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.lungcan.2025.108766","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:46:08Z","timestamp":1758941168000},"page":"108766","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study"],"prefix":"10.1016","volume":"209","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4297-7413","authenticated-orcid":false,"given":"Thomas","family":"Pierret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5807-9503","authenticated-orcid":false,"given":"Laurent","family":"Greillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Guisier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2385-9507","authenticated-orcid":false,"given":"Renaud","family":"Descourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loick","family":"Galland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7965-2989","authenticated-orcid":false,"given":"Olivier","family":"Molinier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Decroisette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Cortot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence Bigay","family":"Gam\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Wislez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9543-0729","authenticated-orcid":false,"given":"Nicolas","family":"Cloarec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3428-506X","authenticated-orcid":false,"given":"Hubert","family":"Curcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Delberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Cadranel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Duchemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Claire","family":"Toffart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Choua\u00efd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Bernard","family":"Auliac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108766_b0005","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non small cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108766_b0010","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2025.108766_b0015","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2025.108766_b0020","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","article-title":"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics","volume":"12","author":"Arcila","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2025.108766_b0025","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3182779d18","article-title":"Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions","volume":"8","author":"Oxnard","year":"2013","journal-title":"J Thoracic Oncol."},{"key":"10.1016\/j.lungcan.2025.108766_b0030","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","article-title":"Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC","volume":"13","author":"Riess","year":"2018","journal-title":"J Thoracic Oncol."},{"key":"10.1016\/j.lungcan.2025.108766_b0035","first-page":"1560","article-title":"Structure and clinical relevance of the epidermal growth factor receptor in human cancer","volume":"13","author":"Kumar","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108766_b0040","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"Shigematsu","year":"2005","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.lungcan.2025.108766_b0045","doi-asserted-by":"crossref","first-page":"S681","DOI":"10.1016\/j.jtho.2019.08.1446","article-title":"Real-world treatment patterns and survival in non-small cell lung cancer patients with EGFR Exon 20 insertion mutations","volume":"14","author":"Dersarkissian","year":"2019","journal-title":"J Thoracic Oncol."},{"key":"10.1016\/j.lungcan.2025.108766_b0050","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108766_b0055","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/annonc\/mdt418","article-title":"Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network","volume":"25","author":"Beau-Faller","year":"2014","journal-title":"Annal Oncol."},{"key":"10.1016\/j.lungcan.2025.108766_b0060","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1002\/cncr.29493","article-title":"Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: clinical outcomes and response to erlotinib","volume":"21","author":"Naidoo","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2025.108766_b0065","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.lungcan.2025.108766_b0070","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw279","article-title":"Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival","volume":"109","author":"Lee","year":"2017","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.lungcan.2025.108766_b0075","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9580","article-title":"Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions","volume":"38","author":"Horn","year":"2020","journal-title":"J Clinical Oncol."},{"key":"10.1016\/j.lungcan.2025.108766_b0080","article-title":"A novel bispecific antibody targeting EGFR and cMet is effective against EGFR Inhibitor (NSCLC) with EGFR exon 20 insertions","volume":"76","author":"Moores","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108766_b0085","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor downmodulation and antitumor activity by monocyte\/macrophage trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.lungcan.2025.108766_b0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cllc.2022.11.004","article-title":"Amivantamab, an epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) bispecific antibody, designed to enable multiple mechanisms of action and broad clinical applications","volume":"24","author":"Cho","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108766_b0095","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on platinum Chemotherapy: initial results from the CHRYSALIS phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108766_b0100","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108766_b0105","article-title":"Molecular epidemiology and treatment patterns of patients with EGFR exon 20-mutant NSCLC in the precision oncology era: the European EXOTIC Registry","volume":"4","author":"Mountzios","year":"2022","journal-title":"JTO Clin Res Rep."},{"key":"10.1016\/j.lungcan.2025.108766_b0110","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.3390\/cancers13205132","article-title":"EGFR exon 20 insertion in metastatic non-small-cell lung cancer: survival and clinical efficacy of EGFR tyrosine-kinase inhibitor and chemotherapy","volume":"13","author":"Chelabi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2025.108766_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107798","article-title":"Clinical outcomes in patients with non-small cell lung cancer harboring EGFR Exon20 in-frame insertions in the near-loop and far-loop: results from LC-SCRUM-Asia","volume":"191","author":"Okahisa","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108766_b0120","article-title":"Real-world response and outcomes in patients with NSCLC with EGFR exon 20 insertion mutations","volume":"4","author":"Ou","year":"2023","journal-title":"JTO Clin Res Rep."},{"key":"10.1016\/j.lungcan.2025.108766_b0125","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jtho.2023.11.020","article-title":"Real-world efficacy and safety of amivantamab for EGFR-mutant NSCLC","volume":"19","author":"Wang","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108766_b0130","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1080\/03007995.2022.2083326","article-title":"Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes","volume":"38","author":"Soeun Kwon","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.lungcan.2025.108766_b0135","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.21037\/tlcr-23-643","article-title":"Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)","volume":"12","author":"Choi","year":"2023","journal-title":"Transl Lung Cancer Res."},{"issue":"44","key":"10.1016\/j.lungcan.2025.108766_b0140","article-title":"Real-world treatment patterns of patients with EGFR exon 20 insertion-mutated advanced NSCLC treated with amivantamab or mobocertinib after platinum-based chemotherapy: a multi-database cohort study","volume":"15","author":"Spira","year":"2025","journal-title":"Cancer Treat Res Commun."},{"key":"10.1016\/j.lungcan.2025.108766_b0145","article-title":"New advances in the treatment of EGFR exon20ins mutant advanced NSCLC","volume":"44 :100944","author":"Yuan","year":"2025","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108766_b0150","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s12325-022-02408-7","article-title":"An adjusted treatment comparison comparing amivantamab versus real-world clinical practice in Europe and the United States for patients with advanced non-small cell lung cancer with activating epidermal growth factor receptor exon 20 insertion mutations","volume":"40","author":"Chouaid","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.lungcan.2025.108766_b0155","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.3390\/cancers15225326","article-title":"Amivantamab compared with real-world physician's choice after platinum-based therapy from a pan-European chart review of patients with lung cancer and activating EGFR exon 20 insertion mutations","volume":"15","author":"Christopoulos","year":"2023","journal-title":"Cancers"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225006580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T04:44:31Z","timestamp":1762490671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225006580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":31,"alternative-id":["S0169500225006580"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108766","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108766","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108766"}}